 <h1>Cabozantinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of cabozantinib include:</b> diarrhea, hypocalcemia, hypertension, and palmar-plantar erythrodysesthesia. <b>Other side effects include:</b> venous thromboembolism, asthenia, fatigue, and decreased appetite.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cabozantinib: oral capsule, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cabozantinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cabozantinib:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>confusion</li>
<li>decreased urination</li>
<li>difficulty with breathing or swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>headache</li>
<li>increase in heart rate</li>
<li>lightheadedness</li>
<li>nervousness</li>
<li>pain in the chest, groin, or legs, especially the calves</li>
<li>pounding in the ears</li>
<li>rapid breathing</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>severe, sudden headache</li>
<li>skin ulcers</li>
<li>slow or fast heartbeat</li>
<li>slurred speech</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
<li>sunken eyes</li>
<li>thirst</li>
<li>unsteadiness or awkwardness</li>
<li>unusual tiredness or weakness</li>
<li>vision changes</li>
<li>weakness in the arms, hands, legs, or feet</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bloody, black, or tarry stools</li>
<li>coughing up blood</li>
<li>heartburn</li>
<li>heavy jaw feeling</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>indigestion</li>
<li>loosening of a tooth</li>
<li>nausea</li>
<li>nosebleeds</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>red or dark brown urine</li>
<li>severe abdominal or stomach pain, cramping, or burning</li>
<li>trouble breathing</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Disturbed color perception</li>
<li>double vision</li>
<li>halos around lights</li>
<li>night blindness</li>
<li>overbright appearance of lights</li>
<li>seizures</li>
<li>tunnel vision</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cabozantinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>bleeding after defecation</li>
<li>change in taste</li>
<li>changes in hair color</li>
<li>decreased appetite</li>
<li>decreased weight</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>dry skin</li>
<li>fear</li>
<li>hair loss or thinning of the hair</li>
<li>hoarseness</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>muscle pain, spasm, or stiffness</li>
<li>pain in the joints</li>
<li>rash</li>
<li>sore throat</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling or inflammation of the mouth</li>
<li>uncomfortable swelling around the anus</li>
<li>voice changes</li>
<li>vomiting</li>
</ul><p>
<!-- end oral capsule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cabozantinib: oral capsule, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Elevated blood pressure (up to 96%), hypertension (up to 61%)</p>
<p><b>Common</b> (1% to 10%): Hypotension, venous thromboembolism, arterial thromboembolism, atrial fibrillation</p>
<p><b>Uncommon</b> (0.1% to 1%): Angina pectoris, supraventricular tachycardia, shortened activated partial thromboplastin time</p>
<p><b>Frequency not reported</b>: QT interval prolongation<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (up to 86%), increased AST (up to 86%), increased alkaline phosphatase (up to 52%), hyperbilirubinemia (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Cholelithiasis</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic encephalopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 63%), stomatitis (up to 51%), nausea (up to 43%), oral pain (up to 36%), constipation (up to 27%), abdominal pain (up to 27%), vomiting (up to 24%), dysphagia (up to 13%), dyspepsia (up to 11%), glossodynia</p>
<p><b>Common</b> (1% to 10%): Hemorrhoids, GI perforation, GI fistula, GI hemorrhage, pancreatitis, anal fissure, anal inflammation, cheilitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Esophagitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Increased blood thyroid stimulating hormone (up to 57%)</p>
<p><b>Common</b> (1% to 10%): Hypothyroidism</p>
<p><b>Uncommon</b> (0.1% to 1%): Amenorrhea<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (up to 53%), neutropenia (up to 35%), thrombocytopenia (up to 35%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased eosinophil count, increased platelet count<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (up to 50%), hair color changes/depigmentation/graying (up to 34%), rash (up to 19%), dry skin (up to 19%), alopecia (up to 16%), erythema (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hyperkeratosis, folliculitis, acne, blister, abnormal hair growth, skin exfoliation, skin hypopigmentation</p>
<p><b>Uncommon</b> (0.1% to 1%): Skin ulcer, telangiectasia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased weight (up to 48%), decreased appetite (up to 46%), hypocalcemia (up to 52%), hypophosphatemia (up to 28%), hypomagnesemia (up to 19%), hypokalemia (up to 18%), hyponatremia (up to 10%), increased blood lactate dehydrogenase, increased blood creatinine phosphokinase</p>
<p><b>Common</b> (1% to 10%): Dehydration, hypoalbuminemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 41%), asthenia (up to 21%), mucosal inflammation</p>
<p><b>Common</b> (1% to 10%): Abscess (including visceral, intra-abdominal, skin, tooth), fungal infection (including skin, oral, genital), ear pain, tinnitus, pallor, peripheral coldness, impaired wound healing/wound complications, chills, face edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Aspergilloma, hypoacusis, cyst, facial pain, localized edema</p>
<p><b>Frequency not reported</b>: Hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (up to 34%), headache (up to 18%), dizziness (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Paresthesia, peripheral sensory neuropathy, peripheral neuropathy, ageusia, tremor</p>
<p><b>Uncommon</b> (0.1% to 1%): Reversible posterior leukoencephalopathy syndrome, ataxia, attention disturbance, loss of consciousness, speech disorder, transient ischemic attack<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 14%), muscle spasms (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal chest pain, osteonecrosis of the jaw (ONJ)</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>General</h3><p>Patients should be closely monitored for the first 8 weeks as most adverse events have occurred early in the course of treatment.</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Proteinuria, dysuria, hematuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Vaginal hemorrhage<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision</p>
<p><b>Uncommon</b> (0.1% to 1%): Cataract, conjunctivitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, confusional state</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, delirium<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dysphonia (up to 20%), oropharyngeal pain</p>
<p><b>Common</b> (1% to 10%): Non-GI fistula (including tracheal, pneumomediastinum, tracheo-esophageal), pulmonary embolism, respiratory tract hemorrhage (including pulmonary, bronchial, tracheal), pneumonia, pneumonia aspiration</p>
<p><b>Uncommon</b> (0.1% to 1%): Atelectasis, pharyngeal edema, pneumonitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Acute renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Cabometyx (cabozantinib)." Exelixis Inc, S San Francisco, CA. </p><p id="ref_2">2. "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the success rate of Cabometyx (cabozantinib)?</li>
<li>How long do you take it for?</li>
<li>Does Cabometyx (cabozantinib) cure cancer?</li>
<li>What is the difference between Cabometyx and Cometriq?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about cabozantinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>10 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cabozantinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cabometyx, Cometriq</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Thyroid Cancer</li>
<li>Renal Cell Carcinoma</li>
<li>Hepatocellular Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cabozantinib: oral capsule, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Elevated blood pressure (up to 96%), hypertension (up to 61%)</p><p><b>Common</b> (1% to 10%): Hypotension, venous thromboembolism, arterial thromboembolism, atrial fibrillation</p><p><b>Uncommon</b> (0.1% to 1%): Angina pectoris, supraventricular tachycardia, shortened activated partial thromboplastin time</p><p><b>Frequency not reported</b>: QT interval prolongation<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (up to 86%), increased AST (up to 86%), increased alkaline phosphatase (up to 52%), hyperbilirubinemia (up to 25%)</p><p><b>Common</b> (1% to 10%): Cholelithiasis</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic encephalopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 63%), stomatitis (up to 51%), nausea (up to 43%), oral pain (up to 36%), constipation (up to 27%), abdominal pain (up to 27%), vomiting (up to 24%), dysphagia (up to 13%), dyspepsia (up to 11%), glossodynia</p><p><b>Common</b> (1% to 10%): Hemorrhoids, GI perforation, GI fistula, GI hemorrhage, pancreatitis, anal fissure, anal inflammation, cheilitis</p><p><b>Uncommon</b> (0.1% to 1%): Esophagitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Increased blood thyroid stimulating hormone (up to 57%)</p><p><b>Common</b> (1% to 10%): Hypothyroidism</p><p><b>Uncommon</b> (0.1% to 1%): Amenorrhea<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (up to 53%), neutropenia (up to 35%), thrombocytopenia (up to 35%)</p><p><b>Uncommon</b> (0.1% to 1%): Increased eosinophil count, increased platelet count<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (up to 50%), hair color changes/depigmentation/graying (up to 34%), rash (up to 19%), dry skin (up to 19%), alopecia (up to 16%), erythema (up to 11%)</p><p><b>Common</b> (1% to 10%): Hyperkeratosis, folliculitis, acne, blister, abnormal hair growth, skin exfoliation, skin hypopigmentation</p><p><b>Uncommon</b> (0.1% to 1%): Skin ulcer, telangiectasia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased weight (up to 48%), decreased appetite (up to 46%), hypocalcemia (up to 52%), hypophosphatemia (up to 28%), hypomagnesemia (up to 19%), hypokalemia (up to 18%), hyponatremia (up to 10%), increased blood lactate dehydrogenase, increased blood creatinine phosphokinase</p><p><b>Common</b> (1% to 10%): Dehydration, hypoalbuminemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 41%), asthenia (up to 21%), mucosal inflammation</p><p><b>Common</b> (1% to 10%): Abscess (including visceral, intra-abdominal, skin, tooth), fungal infection (including skin, oral, genital), ear pain, tinnitus, pallor, peripheral coldness, impaired wound healing/wound complications, chills, face edema</p><p><b>Uncommon</b> (0.1% to 1%): Aspergilloma, hypoacusis, cyst, facial pain, localized edema</p><p><b>Frequency not reported</b>: Hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (up to 34%), headache (up to 18%), dizziness (up to 14%)</p><p><b>Common</b> (1% to 10%): Paresthesia, peripheral sensory neuropathy, peripheral neuropathy, ageusia, tremor</p><p><b>Uncommon</b> (0.1% to 1%): Reversible posterior leukoencephalopathy syndrome, ataxia, attention disturbance, loss of consciousness, speech disorder, transient ischemic attack<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 14%), muscle spasms (up to 12%)</p><p><b>Common</b> (1% to 10%): Musculoskeletal chest pain, osteonecrosis of the jaw (ONJ)</p><p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>General</h3><p>Patients should be closely monitored for the first 8 weeks as most adverse events have occurred early in the course of treatment.</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Proteinuria, dysuria, hematuria</p><p><b>Uncommon</b> (0.1% to 1%): Vaginal hemorrhage<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision</p><p><b>Uncommon</b> (0.1% to 1%): Cataract, conjunctivitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, confusional state</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, delirium<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dysphonia (up to 20%), oropharyngeal pain</p><p><b>Common</b> (1% to 10%): Non-GI fistula (including tracheal, pneumomediastinum, tracheo-esophageal), pulmonary embolism, respiratory tract hemorrhage (including pulmonary, bronchial, tracheal), pneumonia, pneumonia aspiration</p><p><b>Uncommon</b> (0.1% to 1%): Atelectasis, pharyngeal edema, pneumonitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Acute renal failure<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Cabometyx (cabozantinib)." Exelixis Inc, S San Francisco, CA. </p><p id="ref_2">2. "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the success rate of Cabometyx (cabozantinib)?</li>
<li>How long do you take it for?</li>
<li>Does Cabometyx (cabozantinib) cure cancer?</li>
<li>What is the difference between Cabometyx and Cometriq?</li>
</ul><h2>More about cabozantinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>10 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cabozantinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Thyroid Cancer</li>
<li>Renal Cell Carcinoma</li>
<li>Hepatocellular Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>